Study of Panitumumab in the Treatment of Carcinoid Syndrome
The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide or other supportive therapies.
Carcinoid Syndrome
DRUG: Panitumumab
Radiographic measures, Every 4 cycles|Tumor Marker Evaluations, Every 2 cycles
Quality of LIfe, Day 1 each cycle and 1 month follow-up
The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide or other supportive therapies.